UNSPSC 51373335: Bupivacaine/hydromorphone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373335 Bupivacaine/hydromorphone (Commodity) names a specific pharmaceutical ingredient, but recent state and local opportunities tagged under this code do not involve bupivacaine or hydromorphone directly. Instead, they document procurement of naloxone (opioid reversal), safe drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer pharmacy programs. State and local governments are using this code—or codes near it—to buy pharmaceutical products and services for public health initiatives, employee health plans, and institutional health facilities. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which includes Oregon). The scope spans acquisitions of finished pharmaceutical inventory, wholesaler distribution relationships, direct contracting with manufacturers outside traditional pharmacy benefit managers, and compliance with federal drug supply chain security and FDA manufacturing standards.

Recent activity clusters in Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due July 26, 2023—a response date that appears to be a data error in the source. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to explore vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota, Oregon, and other participating jurisdictions through authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson. The MMCAP solicitation weights price competitiveness at 75 percent and requires manufacturers to meet current Good Manufacturing Practices, Drug Supply Chain Security Act compliance, and minimum one-year expiration dates from manufacture.